Show Summary Details
Page of

Metabolic syndrome 

Metabolic syndrome
Metabolic syndrome

Stefania Maggi

and Gaetano Crepaldi

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 01 July 2022

Two of the major determinants of rising healthcare costs in Western society are represented by population ageing, which is accompanied by a parallel increase in age-associated diseases and disabilities, as well as by obesity and its related comorbidities. Many studies have shown that selected risk factors such as impaired glucose tolerance, atherogenic dyslipidemia, and hypertension co-occur to a greater degree than that expected by chance alone in obese individuals (especially in those with central obesity). Their co-occurrence has been defined as ‘metabolic syndrome’, a multifactorial disease of substantial heterogeneity, a major risk factor for type 2 diabetes mellitus, atherosclerotic cardiovascular disease (CVD) and, in the older population, also for cancer, cognitive decline, functional dependence, depression, low quality of life, and mortality. Identifying and treating metabolic syndrome (MS) is thus of vital importance because it could lead to a significant decrease in the burden of morbidity and mortality in older patients.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.